Valeant guidance error

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) continues to fall more than an hour after the company issued a correction to its Tuesday morning earnings release. Upon reporting, Valeant initially said it expected adjusted EBITDA to be between $6.2 billion and $6.6 billion for the next four quarters...